Any serious and/or unstable pre-existing medical, psychiatric, or other existing condition that would prevent compliance with the trial or consent process
Pre-existing Grade  or higher chronic diarrhoea
Pre-existing liver disease
Pre-existing neuropathy greater than or equal to grade 
Patients with pre-existing history of or known cardiovascular risk
Subjects with pre-existing grade II peripheral neuropathy
G> pre-existing peripheral neuropathy
Clinically significant peripheral neuropathy at the time of study entry. Patients with pre-existing peripheral neuropathy will be allowed to receive single agent DKN-
Pre-existing peripheral neuropathy Grade  or higher
Pre-existing neuropathy Grade  or higher
Severe pre-existing ototoxicity or neuropathy that would, in the opinion of the investigator, preclude the use of cisplatin chemotherapy
Serious pre-existing medical conditions as follows:
< Grade  pre-existing peripheral neuropathy per CTCAE
Patients with pre-existing grade >=  peripheral neuropathy
Patients with pre-existing peripheral neuropathy that would limit treatment with taxanes and platinum agents
Has pre-existing brain or bone metastatic lesions.
Skin condition\r\n* Patients with pre-existing grade  or higher ulcerations, fistulas, mucosal lesions, or skin barrier breakdown
Exclude patients with pre-existing neuropathy grade  or higher
Pre-existing and ongoing radiation-related grade  bowel or bladder toxicity
Patients must have < grade  pre-existing peripheral neuropathy (per CTCAE)
History of pre-existing immunodeficiency disorder, autoimmune condition, or chronic infection
Pre-existing peripheral neuropathy of grade II or higher
Pre-existing sensory neuropathy of grade >= 
Pre-existing grade  or  neuropathy
Pre-existing (active or severe) neurologic disorders (e.g. pre-existing seizure disorder)
Pre-existing viral hepatitis
Pre-existing neuropathy greater than grade 
Resectable primary lesion (patients with pre-existing metastasis will be included if their primary is still going to be resected)
Pre-existing liver disease
Patients with pre-existing retinopathy
Pre-existing peripheral neuropathy of severity grade >=  (limiting instrumental activities of daily living)
Pre-existing neuropathy of >= grade 
Pre-existing vocal cord paralysis
Neurological assessment for pre-existing peripheral neuropathy
Patients with pre-existing grade  or greater peripheral neuropathy, defined as sensory alteration or paresthesia (including tingling), interfering with function
MDS evolving from a pre-existing myeloproliferative neoplasm (MPN)
Pre-existing peripheral neuropathy CTCAE grade  or worse
Subjects with existing periorbital edema
Pre-existing peripheral neuropathy grade ?=  at registration
Pre-existing grade  or greater neuropathy
Patients with pre-existing grade  or higher neuropathy or other serious neurologic toxicity that would significantly increase risk of complications from bortezomib therapy are excluded
Pre-existing peripheral neuropathy > grade  with pain (CTC version .).
Any known pre-existing autoimmune disorder
Pre-existing nephritic syndrome
Pre-existing grade >=  peripheral neuropathy
Patients with pre-existing history of or known cardiovascular risk
Pre-existing neuropathy of at least Grade 
Has a pre-existing condition that is contraindicated including
Less than Grade  pre-existing peripheral neuropathy
Pre-existing neuropathy from any cause in excess of Grade .
Pre-existing peripheral neuropathy >= Common Terminology Criteria (CTC) grade  for those patients who received prior paclitaxel
Patients must have recovered from all reversible toxicities related to prior therapy before beginning protocol treatment, and may not have any pre-existing treatment-related toxicities greater than grade ; patients must have < grade  pre-existing peripheral neuropathy
Patients must have < Grade  or pre-existing neuropathy (per CTCAE).
Pre-existing Grade greater than (>)  neuropathy
Pre-existing cardiac conditions
Side effects from prior treatment have not resolved to =< grade  (or baseline due to previously administered agent/pre-existing conditions)
Pre-existing peripheral neuropathy (grade I or higher)
Participant has received treatment with cytarabine for a pre-existing myeloid disorder.
Patients with Grade  or greater pre-existing neurologic abnormalities (CTCAE version .), including Grade  or greater peripheral neuropathy caused by previous treatments.
Pre-existing carotid artery disease
Subjects with pre-existing grade  or  neuropathy; any peripheral neuropathy must recover to grade =<  before enrollment
Pre-existing grade  or  sensory neuropathy
Pre-existing neuropathy greater than grade 
Pre-existing neuropathy greater than grade .
Pre-existing neuropathy grade III or greater
Pre-existing neuropathy from any cause in excess of Grade 
Patients with pre-existing maculopathy or retinopathy of the eye
Patients who have a pre-existing myopathy
Pre-existing peripheral neuropathy >= grade 
History of pre-existing post-traumatic stress disorder (PTSD)
Have serious pre-existing medical conditions.
Pre-existing carotid artery disease.
Have serious pre-existing medical conditions (at the discretion of the investigator).
>= grade  pre-existing peripheral neuropathy (per CTCAEv)
Pre-existing cancers and/or metastatic disease to the adrenal glands
Pre-existing peripheral neuropathy grade >= 
Ongoing treatment for pre-existing cardiovascular disease
Pre-existing neuropathy or severe fluid retention
Pre-existing peripheral neuropathy greater than CTCAE Grade .
Pre-existing >= grade  peripheral neuropathy
Pre-existing limitations on care options, (Do Not Attempt Resuscitation Orders, etc).
Patients with pre-existing neurologic toxicity > grade  (as per CTCAE version .) are not eligible for participation in cohort A; patients screened for participation in cohort B with pre-existing neurologic toxicity > grade  (as per CTCAE, version .) are not eligible, unless pre-existing neurologic toxicity is documented in detail and patient's participation in the trial has been approved by the neuro-oncology team at participating institutions
Patient has pre-existing peripheral neuropathy Grade >
Subject has MDS evolving from a pre-existing myeloproliferative neoplasm (MPN).
Pre-existing symmetric peripheral painful neuropathy
Pre-existing LE prior to their BC diagnosis
Existing CVD
Patients with any pre-existing medical conditions that would be a contraindication to exercise
EXCLUSION - STUDY : Pre-existing neuropathy including CIPN from prior neurotoxic chemotherapy
Pre-existing neutropenia or neutrophil qualitative or quantitative disorder
Pre-existing cytopenia or bone marrow failure syndrome
Self-reported or documented history of pre-existing peripheral neuropathy due to diabetes, human immunodeficiency virus (HIV), or other conditions
Pre-existing active or untreated immunodeficiency disorder and/or chronic use of systemic steroids
Patients with pre-existing medical conditions that would be a barrier to exercise
Other identified causes of painful paresthesias existing prior to chemotherapy (e.g., radiation or malignant plexopathy, lumbar or cervical radiculopathy, pre-existing peripheral neuropathy of another etiology: e.g., carpal tunnel syndrome, B deficiency, acquired immune deficiency syndrome [AIDS], monoclonal gammopathy, diabetes, heavy metal poisoning amyloidosis, syphilis, hyperthyroidism or hypothyroidism, inherited neuropathy, etc.) that might be responsible for the patients current neuropathic symptoms
SCREENING PHASE: Pre-existing peripheral neuropathy within  days of screening consent
INTERVENTION PHASE: Pre-existing peripheral neuropathy within  days of screening consent
Pre-existing grade  or greater neuropathy
History of pre-existing peripheral neuropathy prior to chemotherapy, including alcoholism, vitamin B deficiency, diabetes, human immunodeficiency virus (HIV), congenital neuropathy, toxic neuropathy
Pre-existing alopecia
Patient is using a pre-existing feeding tube for nutritional support at the time of study entry
Subject is using a pre-existing feeding tube for nutritional support at study entry.
Have pre-existing peripheral neuropathy from other medical conditions or due to cancer
Self-reported or documented history of pre-existing peripheral neuropathy prior to initiation of taxane chemotherapy
Pre-existing sensory neuropathy > grade 
